Cover Image

Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study

Show other versions (1)

Talquetamab, a G protein-coupled receptor class C group 5 member D-targeting bispecific antibody for relapsed/refractory multiple myeloma (R/R MM), plus daratumumab, may lead to deeper and more durable responses than either therapy alone. In the phase 1b TRIMM-2 study, patients with R/R MM (at least...

Full description

Saved in:
Bibliographic Details
Main Authors: Chari, Ajai (Author) , van de Donk, Niels W. C. J. (Author) , Dholaria, Bhagirathbhai (Author) , Weisel, Katja (Author) , Mateos, María-Victoria (Author) , Goldschmidt, Hartmut (Author) , Martin, Thomas G. (Author) , Morillo, Daniel (Author) , Reece, Donna (Author) , Rodríguez-Otero, Paula (Author) , Bhutani, Manisha (Author) , D’Souza, Anita (Author) , Oriol, Albert (Author) , Rosiñol, Laura (Author) , Bahlis, Nizar J. (Author) , Vishwamitra, Deeksha (Author) , Skerget, Sheri (Author) , Verona, Raluca I. (Author) , Bakshi, Kalpana (Author) , Kang, Lijuan (Author) , Prior, Thomas J. (Author) , Vandenberk, Lien (Author) , Tolbert, Jaszianne (Author) , Lee, Sangmin (Author) , Smit, M. Damiette (Author) , Wäsch, Ralph (Author)
Format: Article (Journal)
Language:English
Published: December 11 2025
In: Blood
Year: 2025, Volume: 146, Issue: 24, Pages: 2902-2913
ISSN:1528-0020
DOI:10.1182/blood.2025029360
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1182/blood.2025029360
Get full text
Author Notes:Ajai Chari, Niels W.C.J. van de Donk, Bhagirathbhai Dholaria, Katja Weisel, María-Victoria Mateos, Hartmut Goldschmidt, Thomas G. Martin, Daniel Morillo, Donna Reece, Paula Rodríguez-Otero, Manisha Bhutani, Anita D’Souza, Albert Oriol, Laura Rosiñol, Nizar J. Bahlis, Deeksha Vishwamitra, Sheri Skerget, Raluca I. Verona, Kalpana Bakshi, Lijuan Kang, Thomas J. Prior, Lien Vandenberk, Jaszianne Tolbert, Sangmin Lee, M. Damiette Smit, Ralph Wäsch
Description
Summary:Talquetamab, a G protein-coupled receptor class C group 5 member D-targeting bispecific antibody for relapsed/refractory multiple myeloma (R/R MM), plus daratumumab, may lead to deeper and more durable responses than either therapy alone. In the phase 1b TRIMM-2 study, patients with R/R MM (at least 3 previous lines of therapy or double refractory to a proteasome inhibitor and an immunomodulatory drug) received subcutaneous talquetamab 0.4 mg/kg weekly (QW; “QW cohort”) or 0.8 mg/kg every other week (Q2W cohort) plus daratumumab 1800 mg per the approved schedule. The primary end point was safety. Secondary end points included overall response and duration of response. Progression-free survival was an exploratory end point. Sixty-five patients (median 5 previous lines of therapy; 61.5% triple-class refractory; 24.6% bispecific antibody exposed) received talquetamab plus daratumumab (QW, n = 14; Q2W, n = 51; median follow-up of 18.6 months). Most common adverse events were oral events, skin events, cytokine release syndrome, and infections. Grade 3 or 4 events occurred in 81.5%. Two patients had dose-limiting toxicities, both in the Q2W cohort (grade 3 stomatitis/oral mucositis, and grade 3 maculopapular rash). Responses occurred in 71.4% (QW cohort) and 82.4% (Q2W cohort) of patients. Median progression-free survival was 23.3 and 21.2 months, respectively, in each cohort. Pharmacodynamic results suggest the immunomodulatory action of daratumumab contributes to a conducive environment for talquetamab by reducing immunosuppressive cells. Talquetamab plus daratumumab demonstrated promising efficacy outcomes in patients with heavily pretreated disease, with a safety profile consistent with each agent as monotherapy. This trial was registered at www.clinicaltrials.gov as #NCT04108195.
Item Description:Gesehen am 20.02.2026
Physical Description:Online Resource
ISSN:1528-0020
DOI:10.1182/blood.2025029360

Similar Items